Literature DB >> 15137338

Influence of contrast agent dose and image acquisition timing on the quantitative determination of nonviable myocardial tissue using delayed contrast-enhanced magnetic resonance imaging.

Steffen E Petersen1, Oliver K Mohrs, Georg Horstick, Katja Oberholzer, Nico Abegunewardene, Kordula Ruetzel, Joseph B Selvanayagam, Matthew D Robson, Stefan Neubauer, Manfred Thelen, Juergen Meyer, Karl-Friedrich Kreitner.   

Abstract

BACKGROUND: Delayed contrast-enhanced magnetic resonance imaging (ceMRI) has been shown to identify areas of irreversible myocardial injury due to infarction (MI) with high spatial resolution, allowing precise quantification of nonviable (hyperenhanced) myocardium. The aim of our study was to investigate the size of nonviable myocardium quantitatively as a function of time post-contrast when inversion time is held constant in patients post-myocardial infarction using two contrast agent (CA) doses.
METHODS: Nine patients with chronic MI underwent two MR scans on a 1.5 Tesla system. Contrast-enhanced MRI data in two short-axis (SA) slices were continuously acquired until 40 minutes after CA injection [gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA), 0.1 mmol/kg body weight = single dose] interrupted only for a complete stack of SA slices encompassing the entire left ventricle (LV) between minutes 20 and 28. Left ventricular mass showing hyperenhancement was determined. The measurement was repeated on the subsequent day with double dose CA (0.2 mmol/kg body weight). Differences of signal intensities for hyperenhanced, nonhyperenhanced myocardium, and LV cavity were calculated.
RESULTS: Total mass of hyperenhancement from a complete SA stack acquired between minutes 20 and 28 was lower for single dose CA [9.0% vs. 14.2% for single and double dose, respectively (p = 0.03)]. Ten to 18 minutes after CA injection, there was no significant difference between the two doses and to an internal reference for both single and double dose. For single dose the image contrast between hyperenhancement and LV cavity was superior (minutes 10 to 16, p < 0.05) but inferior between hyperenhanced and nonhyperenhanced myocardium (minutes 6 to 16, p < 0.05).
CONCLUSION: Myocardial infarct size measurements are a function of time postcontrast when inversion time is held constant regardless of the contrast agent dose. These data underscore the fact that a standardized imaging protocol that defines how the appropriate inversion time should be selected is needed for comparison of results obtained at various cMR sites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15137338     DOI: 10.1081/jcmr-120030581

Source DB:  PubMed          Journal:  J Cardiovasc Magn Reson        ISSN: 1097-6647            Impact factor:   5.364


  12 in total

1.  Optimization of myocardial nulling in pediatric cardiac MRI.

Authors:  Edythe B Tham; Ryan W Hung; Kimberley A Myers; Cinzia Crawley; Michelle L Noga
Journal:  Pediatr Radiol       Date:  2011-10-18

2.  Cardiac magnetic resonance versus SPECT: are all noninfarct myocardial regions created equal?

Authors:  Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2007-01       Impact factor: 5.952

3.  Quantitative inversion time prescription for myocardial late gadolinium enhancement using T1-mapping-based synthetic inversion recovery imaging: reducing subjectivity in the estimation of inversion time.

Authors:  Sebastian Gassenmaier; Rob J van der Geest; U Joseph Schoepf; Pal Suranyi; Wolfgang G Rehwald; Carlo N De Cecco; Domenico Mastrodicasa; Moritz H Albrecht; Domenico De Santis; Virginia W Lesslie; Balazs Ruzsics; Akos Varga-Szemes
Journal:  Int J Cardiovasc Imaging       Date:  2018-01-05       Impact factor: 2.357

4.  Effect of inversion time on the precision of myocardial late gadolinium enhancement quantification evaluated with synthetic inversion recovery MR imaging.

Authors:  Akos Varga-Szemes; Rob J van der Geest; U Joseph Schoepf; Bruce S Spottiswoode; Carlo N De Cecco; Giuseppe Muscogiuri; Julian L Wichmann; Stefanie Mangold; Stephen R Fuller; Pal Maurovich-Horvat; Bela Merkely; Sheldon E Litwin; Rozemarijn Vliegenthart; Pal Suranyi
Journal:  Eur Radiol       Date:  2017-01-03       Impact factor: 5.315

5.  Role of first pass and delayed enhancement in assessment of segmental functional recovery after acute myocardial infarction.

Authors:  L Natale; C Napolitano; A Bernardini; A Meduri; R Marano; A Lombardo; F Crea; L Bonomo
Journal:  Radiol Med       Date:  2012-03-19       Impact factor: 3.469

6.  Contrast-enhanced adenosine-stress magnetic resonance imaging--feasibility and practicability of a protocol for detection or exclusion of ischemic heart disease in an outpatient setting.

Authors:  P Bernhardt; B Levenson; T Engels; O Strohm
Journal:  Clin Res Cardiol       Date:  2006-07-14       Impact factor: 5.460

7.  Advanced methods for quantification of infarct size in mice using three-dimensional high-field late gadolinium enhancement MRI.

Authors:  Steffen Bohl; Craig A Lygate; Hannah Barnes; Debra Medway; Lee-Anne Stork; Jeanette Schulz-Menger; Stefan Neubauer; Jurgen E Schneider
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-13       Impact factor: 4.733

8.  Rapid T1 quantification based on 3D phase sensitive inversion recovery.

Authors:  Marcel J B Warntjes; Johan Kihlberg; Jan Engvall
Journal:  BMC Med Imaging       Date:  2010-08-17       Impact factor: 1.930

9.  Late gadolinium enhancement magnetic resonance imaging for the assessment of myocardial infarction: comparison of image quality between single and double doses of contrast agents.

Authors:  Yeo Koon Kim; Eun-Ah Park; Whal Lee; Sang Yoon Kim; Jin Wook Chung
Journal:  Int J Cardiovasc Imaging       Date:  2014-08-03       Impact factor: 2.357

10.  Left ventricular infarct size assessed with 0.1 mmol/kg of gadobenate dimeglumine correlates with that assessed with 0.2 mmol/kg of gadopentetate dimeglumine.

Authors:  Monravee Tumkosit; Chirapa Puntawangkoon; Tim M Morgan; Hollins P Clark; Craig A Hamilton; William O Ntim; Paige B Clark; W Gregory Hundley
Journal:  J Comput Assist Tomogr       Date:  2009 May-Jun       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.